Lipoxin A4 Ameliorates Imiquimod-Induced Psoriasis-Like Dermatitis via Promoting the Regression of Inflammation.
Th17
imiquimod
inflammation
lipoxin A4
psoriasiform dermatitis
γδT cells
Journal
Clinical, cosmetic and investigational dermatology
ISSN: 1178-7015
Titre abrégé: Clin Cosmet Investig Dermatol
Pays: New Zealand
ID NLM: 101543449
Informations de publication
Date de publication:
2023
2023
Historique:
received:
23
05
2023
accepted:
03
08
2023
medline:
14
8
2023
pubmed:
14
8
2023
entrez:
14
8
2023
Statut:
epublish
Résumé
As a mediator of inflammation resolution, lipoxin A4 (LXA4) mainly plays an anti-inflammatory role and promotes inflammation resolution. LXA4 plays an inhibiting inflammatory role in a variety of diseases, tissues and cells, including keratinocytes. Psoriasis is a chronic inflammatory skin disease mediated by dysregulation of inflammation of immune cells and keratinocytes. However, the expression and role of LXA4 in psoriasis-like mouse models are still unclear. Imiquimod (IMQ) topical treatment of dorsal skin induces psoriasis-like dermatitis in BALB/c mice, pretreated intraperitoneally with or without LXA4 prior to IMQ application. Severity of dorsal lesions is assessed by using a modified human scoring system and histopathology. The concentration of LXA4 and the expression of ALOX15 (a key gene in LXA4 metabolic synthesis) in lesional skins were detected by ELISA and Western blot. Quantitative PCR and ELISA were conducted to detect the mRNA and secretion levels of inflammatory cytokines. The proportion of IL-17A-producing γδT cells in skin and skin draining cervical lymph nodes and helper (Th) 17 cells in spleens was evaluated by flow cytometry. Western blotting was used to analyze the expressions of p-STAT3 and TRAF6. The concentration of LXA4 and the expression of ALOX15 were decreased in IMQ-induced lesional skin. LXA4 significantly relieved psoriasis-like lesions in IMQ-induced mouse models. Furthermore, LXA4 decreased IMQ-induced systemic inflammation, including reduced the proportion of IL-17A-producing gdT cells in skin and skin draining cervical lymph nodes and Th17 cells in spleens, the secretion and expression of CCL20, IL-17A, IL-1β, and TNF-α in skin and serum. LXA4 markedly inhibited IMQ-induced expression of TRAF6 and p-STAT3. LXA4 significantly ameliorates IMQ-induced psoriasis-like inflammation, and LXA4 can be used as a target for psoriasis treatment.
Identifiants
pubmed: 37575152
doi: 10.2147/CCID.S418467
pii: 418467
pmc: PMC10422962
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2103-2111Informations de copyright
© 2023 Hu et al.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest in this work.
Références
Immunity. 2011 Oct 28;35(4):596-610
pubmed: 21982596
J Am Acad Dermatol. 2022 Oct;87(4):800-806
pubmed: 35772599
J Invest Dermatol. 2009 Jun;129(6):1339-50
pubmed: 19322214
J Immunol. 2011 Jun 1;186(11):6091-5
pubmed: 21536803
Biochem Pharmacol. 2021 Nov;193:114759
pubmed: 34487716
J Alzheimers Dis. 2021;79(2):607-613
pubmed: 33337374
Proc Natl Acad Sci U S A. 2015 Jun 30;112(26):8046-51
pubmed: 26080440
Lancet. 2021 Feb 20;397(10275):754-766
pubmed: 33515492
Proc Natl Acad Sci U S A. 2020 Apr 7;117(14):7971-7980
pubmed: 32205444
EBioMedicine. 2022 Aug;82:104136
pubmed: 35785620
Biomed Pharmacother. 2019 Sep;117:109099
pubmed: 31200255
J Immunol. 2009 May 1;182(9):5836-45
pubmed: 19380832
J Inflamm Res. 2021 Apr 12;14:1375-1385
pubmed: 33880053
J Immunol. 2011 Nov 15;187(10):5026-31
pubmed: 21984702
ACS Pharmacol Transl Sci. 2020 Jan 17;3(1):43-55
pubmed: 32259087
J Invest Dermatol. 2019 Jan;139(1):146-156
pubmed: 30120937
J Dermatol Sci. 2015 Jun;78(3):181-8
pubmed: 25847211
Reprod Sci. 2018 Apr;25(4):566-578
pubmed: 28691579
Lancet. 2021 Apr 3;397(10281):1301-1315
pubmed: 33812489
J Allergy Clin Immunol. 2016 Aug;138(2):517-528.e5
pubmed: 27315769
JAMA. 2020 May 19;323(19):1945-1960
pubmed: 32427307
Expert Opin Drug Metab Toxicol. 2019 Nov;15(11):913-925
pubmed: 31623470
Front Immunol. 2020 Jul 14;11:1447
pubmed: 32760397
J Huazhong Univ Sci Technolog Med Sci. 2015 Jun;35(3):426-431
pubmed: 26072084
Nat Commun. 2015 Jul 15;6:7687
pubmed: 26173479
J Dermatol. 2020 Feb;47(2):104-113
pubmed: 31833093
J Invest Dermatol. 2008 May;128(5):1064-7
pubmed: 18408745
Inflammation. 2022 Oct;45(5):1950-1967
pubmed: 35438373
Phytother Res. 2021 Aug;35(8):4526-4537
pubmed: 34008239
J Neurosurg Sci. 2018 Apr;62(2):225-226
pubmed: 28869373
Sci Rep. 2018 Jun 11;8(1):8856
pubmed: 29891910
Br J Pharmacol. 2017 Nov;174(22):4043-4054
pubmed: 28071789
Eur J Pharmacol. 2016 Feb 5;772:131-43
pubmed: 26738780
Bone. 2020 Nov;140:115538
pubmed: 32730926